$35.59
+0.03
(+0.08%)▲
1.1%
Downside
Day's Volatility :2.11%
Upside
1.03%
47.71%
Downside
52 Weeks Volatility :52.6%
Upside
9.36%
Period | Harmony Biosciences Holdings Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 16.69% | 5.1% | 0.0% |
6 Months | 14.66% | 4.9% | 0.0% |
1 Year | -6.34% | 16.6% | 0.0% |
3 Years | -5.85% | 13.2% | -22.3% |
Market Capitalization | 2.0B |
Book Value | $9.48 |
Earnings Per Share (EPS) | 1.95 |
PE Ratio | 18.25 |
Wall Street Target Price | 43.29 |
Profit Margin | 17.53% |
Operating Margin TTM | 12.36% |
Return On Assets TTM | 13.75% |
Return On Equity TTM | 22.47% |
Revenue TTM | 656.1M |
Revenue Per Share TTM | 11.33 |
Quarterly Revenue Growth YOY | 28.799999999999997% |
Gross Profit TTM | 354.4M |
EBITDA | 202.5M |
Diluted Eps TTM | 1.95 |
Quarterly Earnings Growth YOY | -0.64 |
EPS Estimate Current Year | 2.24 |
EPS Estimate Next Year | 3.73 |
EPS Estimate Current Quarter | -0.06 |
EPS Estimate Next Quarter | 0.65 |
What analysts predicted
Upside of 21.64%
Sell
Neutral
Buy
Harmony Biosciences Holdings Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Harmony Biosciences Holdings Inc | 6.08% | 14.66% | -6.34% | -5.85% | -3.84% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Harmony Biosciences Holdings Inc | 18.25 | 18.25 | NA | 2.24 | 0.22 | 0.14 | NA | 9.48 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Harmony Biosciences Holdings Inc | Buy | $2.0B | -3.84% | 18.25 | 17.53% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Harmony Biosciences Holdings Inc
Revenue is up for the last 2 quarters, 154.61M → 172.81M (in $), with an average increase of 10.5% per quarter
Netprofit is down for the last 2 quarters, 38.33M → 11.59M (in $), with an average decrease of 69.8% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 43.4%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 75.0%
Valor Management LLC
BlackRock Inc
FMR Inc
Vanguard Group Inc
Vivo Capital, LLC
State Street Corporation
patients are at the beginning, middle, and heart of all we do. harmony biosciences, llc, is a privately-owned biopharmaceutical company. the company was established in october 2017 with a vision to provide novel treatment options for people living with rare and orphan diseases with an emphasis on central nervous system disorders, starting with a focus on helping patients who live with narcolepsy. harmony biosciences is committed to advancing the understanding of narcolepsy and providing information and resources to individuals who live with, and healthcare professionals who treat, patients with narcolepsy.
Organization | Harmony Biosciences Holdings Inc |
Employees | 246 |
CEO | Mr. Jeffrey S. Aronin |
Industry | Health Technology |